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Table 1
Characteristics of Patients with Graft Failure
Pt Diagnosis 1st graft Conditioning
1st graft
Graft
failure
Chimerism
CD3%/CD33%
2nd graft Same
than 1st
graft
Conditioning
2nd graft
Poor
graft
function
Chimerism
CD3%/CD33%
Outcome
from 2nd
graft
1 Post-ET MF VUD 10/10 Flu/Mel 2ry 10/98 VUD 10/10 no Flu/Cy/TBI200 no 100/100 Died, GVHD
2 Post-PV MF MMRD 9/10 Flu/Mel 1ry N/A VUD 9/10 yes Flu/Cy/TBI200 no 100/100 Alive 58 mo
3 PMF VUD 10/10 Flu/Mel/rATG 1ry N/A VUD 10/10 yes Flu/TBI200 yes 100/100 Died, GVHD
4 PMF
transformed
to AML
VUD 9/10 Flu/Bu/rATG 1ry N/A VUD 10/10 no Flu/Mel/Thio no 100/100 Alive 9 mo
5 Post-PV MF VUD 10/10 Flu/Mel 2ry 76/0 N/A N/A N/A no N/A Died,
pneumonia
6 PMF VUD 9/10 (DQ) Flu/Bu/rATG 2ry 0/100 N/A N/A N/A yes N/A Alive 3 mo
RIC-HSCT for MF still counts with signiﬁcant hurdles including primary and secondary GF. Use of unrelated, mismatched donors, RIC conditioning, and in vivo T-
cell depletion are potential risk factors for GF. Highly immunosuppressive non-myeloablative conditioning combining ﬂudarabine and low dose TBI promotes a
successful engraftment and can be used to salvage these patients.
Re-transplantation following graft failure is feasible. Further studies regarding optimal conditioning regimens are needed.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S295post-PV/-ET (8/20 transformed to AML)] underwent RIC pe-
ripheral blood stem cell (PBSC) transplantation. RIC included
Flu/Bu (5 patients), Flu/Bu/rATG (4 patients), Flu/Mel (20
patients) and Flu/Mel/rATG (11 patients). GVHD prophylaxis
was administered as FK/MTX (38 patients), CSA/MTX (1 pa-
tient) and CSA/MMF (3 patients). Sixteen were related do-
nors, and 26 unrelated; 36 donors were 10/10 and 6 were 9/
10 HLA matched. A JAK2 inhibitor was administered to 19
patients prior to HSCT. Mean and median OS were 24 and 13
months (range 1-79). Seventeen patients survived more than
2 years, and 7 are alive >5 years from second transplant.
Neutrophil engraftment, median 13 days (range 10-40);
platelet engraftment, median 20 days (range 11-87) with 10
patients failing to engraft platelets. For acute GVHD, 25 pa-
tients developed grade II-IV, and 8 patients developed
chronic GVHD. Six patients (14%) developed GF (4 primary, 2
secondary).421
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Background: Acute erythroid leukemia (AEL) is a rare sub-
type of AMLwith a relatively poor prognosis. Allogeneic stem
cell transplant (alloSCT) improves the outcomes of AEL;
however, only a small number (19%) of patients are typically
able to receive alloSCT (Blood 2010; 115: 1985).
Method: We retrospectively analyzed the outcomes of pa-
tients diagnosed with AEL (May 2008-January 2014) at Uni-
versity of Massachusetts Medical Center with respect to
alloSCT.
Results: Fourteen patients (3 females) were identiﬁed, me-
dian age was 73.2 years (range, 27-91) at diagnosis, 5 (35.7%)
were over the age of 80 years. At diagnosis median white
blood cell count was 1700 cells/mcL (range, 600-11,700),
hemoglobin was 9 grams/dL (range, 7.7-12.2) and platelet
count was 56,000 cells/mcL (range, 11,000-166,000). Six
(42.8%) patients had high risk disease based on the karyo-
type, 5 (35.7%) were tested for FLT3 and NPM1 mutation and
all of them were negative. Two (14.2%) patients had a prior
history of MDS. As initial therapy 6 (42.8%) patients received
a hypomethylating agent, 5 (35.7%) received induction
chemotherapy with high dose cytarabine/mitoxanthrone. Six
(42.8%) patients underwent alloSCT after receiving a reduced
intensity conditioning regimen. All of themwere in complete
remission prior to transplant. Median time to transplant was
4.9 months (range, 2.6-7.3). One of the six (16.6%) patients
developed acute GVHD, and 3 (50%) had chronic GVHD.
The median OS was 16.7 months (range, 0-36.5) of all AEL
patients. Patients whowere able to undergo an alloSCT had a
superior overall survival of 33months compared to 7months
without transplant (p¼0.036).
Conclusion: Our institutional experience conﬁrms that sur-
vival of patients with AEL can be signiﬁcantly improved by
allogeneic stem cell transplantation. Investigation of strate-
gies that will enable more AEL patients to receive allogeneic
SCT are warranted.422
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